Publication details
Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)
| Basic information | |
|---|---|
| Original title: | Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade) |
| Authors: | Romana Zaoralová, Petr Kuglík, Hana Filková, Henrieta Grešliková, Pavel Němec, Alexandra Oltová, Luděk Pour, Zdeněk Adam, Andrea Křivanová, Marta Krejčí, Roman Hájek |
| Information from University Press | |
|---|---|
| Price: | Not for sale |
| Publisher within MU: | Faculty of Medicine |
| Further information | |
|---|---|
| Citation: | ZAORALOVÁ, Romana, Petr KUGLÍK, Hana FILKOVÁ, Henrieta
GREŠLIKOVÁ, Pavel NĚMEC, Alexandra OLTOVÁ, Luděk POUR, Zdeněk
ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Clinical
implications of chromosomal aberrations (13q14 and 17p13
deletion, translocation t(4;14) and 1q21 amplification) in
patients with relapsed multiple myeloma treated by thalidomide
or bortezomib (Velcade). In From cell sorting to plasma cell
identification and chromosomal aberrations in multiple myeloma
– Application manual. Brno: vydavatelství Masarykovy
Univerzity, 2007. p. 12 -13, 2 pp. ISBN 978 -80 -210 -4417 -3.Export BibTeX |
| Original language: | English |
| Field: | Genetics and molecular biology |
| Type: | Article in Proceedings |
| Keywords: | Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH |
The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens.
Related projects:












